Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas’ PADCEV, all alongside a frenzy of companies entering the field and billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.

Returning as industry’s definitive ADC forum from early discovery to late-phase manufacturing, the 15th World ADC San Diego is the world-leading, largest, and most comprehensive ADC-focused conference to maximize the therapeutic window of ADCs. Whether you have just ventured into the ADC space or are an ADC guru, you’ll leave this meeting with the insight and connections needed to overcome your challenges and make impactful strides in your work.

Uniting over 1,200 ADC enthusiasts from field novices to long-standing KOLs including experts from Daiichi Sankyo, Pfizer, AbbVie, AstraZeneca, and ADC Therapeutics, World ADC San Diego is the annual community touchpoint to gain unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends to progress ADCs to new standard of care treatments in oncology and beyond.

Event link here.